About
About Enara Bio
The Team
Board of Directors
Scientific Advisory Board
Technology
Products
Partners
Careers
News
Contact
News
Enara Bio highlights Dark Antigens® as a novel class of targets for developing targeted immunotherapies against solid tumors
Enara Bio’s unique approach identifying Dark Antigen® candidates and cognate T cells in non-small-cell lung cancer and melanoma detailed in two posters to be presented at the 37th Society for Immunotherapy of Cancer Annual Meeting
10th November 2022
Enara Bio’s Dark Antigen presentations from the 37th Society for Immunotherapy of Cancer Annual Meeting
2nd November 2022
ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research
23rd May 2022
Enara Bio’s presentation on development of an MR1-targeting T cell therapy from the 12th International CD1-MR1 EMBO Meeting
9th May 2022
Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting
1st February 2022
Enara Bio announces the appointment of T-cell therapy leader Dr. Sophie Papa as Chief Medical Officer
Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) where she was a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist.
28th September 2021
Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors
Enara Bio announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director
21st June 2021
Enara Bio participates in Boehringer Ingelheim’s “Taking Cancer On” podcast series
Enara Bio is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today.
9th June 2021
Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit
Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June.
9th March 2021
Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team
Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research